Results 121 to 130 of about 1,394 (181)

A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease. [PDF]

Cureus
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Matsuyama K, Kato N, Kawamoto A, Kawakami A.   +16 more
europepmc   +1 more source

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

, 2020
David C. Fajgenbaum, David Wu, Aaron M. Goodman, Raymond Wong, Amy Chadburn, Sunita D. Nasta, Gordan Srkalović, Sudipto Mukherjee, Heather A. Leitch, Raj Jayanthan, Simone Ferrero, Yasuharu Sato, Steve Schey, Angela Dispenzieri, Éric Oksenhendler, Pier Luigi Zinzani, Mary Jo Lechowicz, Christian Hoffmann, Naveen Pemmaraju, Adam Bagg, Alexander Fosså, Megan S. Lim, Frits van Rhee, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group   +23 more
openalex   +2 more sources

Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease

Melanie Mumau, Michael Gonzalez, Katherine S. Forsyth, M. Betina Pampena, Abiola Irvine, Criswell Lavery, Joseph Zinski, Ira D. Miller, Thomas Barnett Dubensky, Derek A. Oldridge, Laura A. Vella, Michael R. Betts, David C. Fajgenbaum   +12 more
openalex   +2 more sources

Disseminated dermatophytosis in a patient with idiopathic multicentric Castleman disease on siltuximab therapy — a case report

Katarzyna Piszczek-Onak, Przemysław Hałubiec, Agnieszka Giza, Paweł Krzyściak, Grzegorz Dyduch, Anna B. Wojas-Pelc, Andrzej K. Jaworek   +6 more
openalex   +2 more sources

TAFRO subtype of idiopathic multicentric Castleman disease in a 22-year-old man. [PDF]

CMAJ
Rowe S, Collins BW, Pirzada A, Manning N, Chen LYC.   +4 more
europepmc   +1 more source

Prognostic value of serum C-reactive protein in idiopathic multicentric Castleman disease and construction of a prognostic model for patients. [PDF]

Front Med (Lausanne)
Lei Z, Wang Y, Yu T, Zhang Y, Cui W, Luo C, Luo Q, Zhou L, Gao Y, Yu L.   +9 more
europepmc   +1 more source

No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis. [PDF]

Sci Rep
Miller I, Mumau MD, Shyamsundar S, Sarmiento Bustamante M, Horna P, Gonzalez MV, Fajgenbaum DC.   +6 more
europepmc   +1 more source

T follicular helper cells are mis-localized in idiopathic multicentric castleman disease [PDF]

Melanie Mumau, Katherine S. Forsyth, Michael V. Gonzalez, Joseph Zinski, Abiola Irvine, David C. Fajgenbaum   +5 more
openalex   +1 more source

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients. [PDF]

Front Immunol
Feng A, Gonzalez MV, Kalaycioglu M, Yin X, Mumau M, Shyamsundar S, Bustamante MS, Chang SE, Dhingra S, Dodig-Crnkovic T, Schwenk JM, Garg T, Yoshizaki K, van Rhee F, Fajgenbaum DC, Utz PJ.   +15 more
europepmc   +1 more source

Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab. [PDF]

Intern Med
Tsuzuki Wada T, Yokota K, Okada M, Ichimura T, Ueno T, Okumura N, Osawa I, Inoue K, Akiyama Y, Nakazato Y, Sasaki A, Yamamoto T, Mimura T.   +12 more
europepmc   +1 more source